Abstract
THE RECENT LICENSING OF A NEW meningococcal conjugate vaccine has prompted government officials to expand recommended immunization practices. The new vaccine is expected to drastically reduce the prevalence of invasive meningococcal disease caused by Neisseria meningitidis serogroups A C Y and W-135 which make up the majority of cases in the United States. The Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention (CDC) recommended on February 10 that children aged 11 and 12 years teens entering high school and college freshman living in dormitories receive meningococcal (groups A C Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra). This vaccine manufactured by Sanofi Pasteur (Swiftwater Pa) received US Food and Drug Administration approval on January 14 2005. (excerpt)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
